Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

NCT07451912 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
CEBPA Mutation
Unfit, New-diagnosis AML

Interventions

DRUG: Venetoclax + Hypomethylating Agents + Low-Dose Cytarabine for CEBPA-Mutated AML (Unfit Patients)

Sponsor

The First Affiliated Hospital of Soochow University